Combining targeted therapies in ovarian cancer
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference10 articles.
1. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N Engl J Med,2011
2. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial;Ledermann;Lancet Oncol,2014
3. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study;Gelmon;Lancet Oncol,2011
4. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2;Mathews;Arterioscler Thromb Vasc Biol,2008
5. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130;Hegan;Proc Natl Acad Sci USA,2010
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Parp Inhibitors for the Treatment of Ovarian Cancer;Current Cancer Drug Targets;2018-10-17
2. IL-36α suppresses proliferation of ovarian cancer cells;Tumor Biology;2017-06
3. HOTAIR rs920778 polymorphism is associated with ovarian cancer susceptibility and poor prognosis in a Chinese population;Future Oncology;2017-02
4. High expression of CDC6 is associated with accelerated cell proliferation and poor prognosis of epithelial ovarian cancer;Pathology - Research and Practice;2016-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3